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ACUTE INFLAMMATION AND ELEVATED 
CARDIAC MARKERS IN A TWO-MONTH-OLD 
INFANT WITH SEVERE ACUTE RESPIRATORY 
SYNDROME CORONAVIRUS 2 INFECTION 
PRESENTING WITH CARDIAC SYMPTOMS
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Abstract: Severe acute respiratory syndrome coronavirus 2 infection in 
children mainly shows a milder course. In complicated cases, it is unknown 
whether inflammation is predictive of disease severity, as in adults. Moreo-
ver, cardiac involvement is anecdotally described. We report the case of a 
2-month-old infant with severe acute respiratory syndrome coronavirus 2 
infection presenting with fever, tachycardia and elevated interleukin-6, who 
was diagnosed with myocarditis and treated with immunoglobulins.
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a public health emergency worldwide. In 
adults, the disease varies in its clinical presentation from a flu-like 
syndrome with fever, cough, myalgia and/or fatigue to respiratory 
failure as the major leading cause of death. Despite respiratory 
symptoms are dominant in complex cases, cardiac involvement 
has been lately described as a clinical complication. In adults with 
consequently, leading to a good outcome. He also had a respiratory 
implication of SARS-CoV2 but not as severely described as in the 
adult ARDS.
The high clinical suspicion of myocarditis in our patient 
based on clinical course and elevated myocyte cytolysis markers 
was confirmed by the functional and structural CMR findings, 
combining main and supportive criteria according to the cur-
rent guidelines8 and the revised Lake-Louise recommendations.9 
Myocarditis due to viral infection has been widely described and 
associated to myocardial inflammation leading to necrosis and 
heart dysfunction. Other coronaviruses (Middle East Respiratory 
Syndrome Coronavirus) have already been identified as causative 
agents of myocarditis in adults.5 In the case of COVID-19, the 
physiopathologic process remains unclear, although both direct 
cardiac injury by SARS-CoV2 (eg, through ACE2 binding in the 
heart) and indirect damage through a toxic inflammatory reaction 
with cytokine storm seem plausible. Several adult autopsy reports 
revealed that there is a significant number of inflammatory cells 
in the alveoli of patients suffering from ARDS caused by SARS-
CoV2.10 Nevertheless, no histologic changes were seen in heart 
tissue and no viral inclusions were identified in the lungs, sug-
gesting indirect damage through the cytokine storm. Furthermore, 
high rates of inflammatory markers such as IL-6, Ferritin or CRP 
can be found in the blood of critical patients. Our patient with 
myocarditis responded to immunomodulatory treatment, with a 
complete reversal of myocardial edema, raising the hypothesis 
that SARS-CoV2 triggers an exaggerated inflammatory response 
causing heart damage. Further argument to highlight the physi-
opathologic process as a para-infectious inflammatory response to 
SARS-CoV2 in our patient is that viral load was low (high CT), 
suggesting that he was at the end of the infection but in the middle 
of the cytokine storm.
A hypothesis to explain the death of children occurring dur-
ing COVID-19 could be that some predisposed children might be 
more susceptible to cardiac damages from the cytokine storm trig-
gered by COVID-19 rather than the usual respiratory distress syn-
drome typically observed in adults. Deep analysis of pediatric life-
threatening infections is necessary to better understand children’s 
specific risk factors.
CONCLUSION
During this time of pandemic, where telemedicine is becom-
ing a common practice, it is essential that whenever any sign of 
potential gravity is present at a child’s evaluation, urgent clinical 
care is provided to identify potential life-threatening COVID-19 
such as myocarditis.
Therefore, clinicians should be aware of the cardiac involve-
ment of SARS-CoV2 in children and search for any signs of myo-
carditis when taking care of unwell children with proven or sus-
pected COVID-19 as prompt diagnosis can be lifesaving.
We also raise concerns that cardiac injury could be due to 
the disproportionate host immune response to SARS-CoV2 rather 
than through direct damage by the virus itself.
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severe illness, elevated inflammatory cytokines seem to play a major 
role and have been proposed as a predictor of disease severity.1
In infants and children, SARS-CoV-2 infection mainly 
shows a milder course, with only few cases of acute respiratory 
disease reported. Moreover, cardiac injury related to SARS-CoV-2 
has only been described in a 55-day-old infant, and no correlation 
with inflammation markers has been proven.2 Here, we report the 
case of a 2-month-old child affected by SARS-CoV-2 presenting 
with fever, tachycardia and elevated interleukin-6 (IL-6), who was 
diagnosed with suspected myocarditis.
CASE REPORT
A 2-month-old child was admitted to our hospital because of 
a 2-day history of fever (38°C), nonbloody diarrhea and 2 episodes 
of vomiting.
Because a recent close contact with confirmed cases of coro-
navirus disease 2019 (COVID-19; her father and her older brother) 
was reported, a nasopharyngeal swab was performed and analyzed 
using real-time reverse transcriptase polymerase chain reaction 
essay, resulting positive for SARS-CoV-2.
At the time of admission, the baby was presenting with whiny 
crying, intermittent tachycardia (heart rate between 170 and 230 bpm) 
and mottled skin. The temperature was 37.4°C, the respiratory rate was 
40 breaths per minute and the oxygen saturation was 96% breathing 
room air. The blood pressure was 88/50 mm Hg. Physical examina-
tion was otherwise normal, with no signs of respiratory or neurologic 
impairment. Arterial blood gas analysis parameters were within nor-
mal limits. Chest radiography was unremarkable. Two 12-lead elec-
trocardiograms, 3 hours apart, confirmed sinus tachycardia, without 
other clear pathologic alterations. Transthoracic echocardiography 
revealed no pathologic signs. Blood tests showed normal C-reactive 
protein, procalcitonin (PCT), blood cell count and a slightly decreased 
hemoglobin concentration. However, a routine cardiac panel revealed 
an increase in plasma levels of troponin T (103 ng/L) and N-terminal 
pro-brain natriuretic peptide (12,507 ng/L), alongside with elevated 
concentrations of IL-6 (236 ng/L). As a precautionary measure, 
empiric treatment with intravenous cefotaxime plus ampicillin was 
started and the infant was transferred to the pediatric intensive care 
unit with the diagnostic suspect of myocarditis.
At admission to the pediatric intensive care unit depart-
ment, on day 2 after arrival, blood tests showed increased C-reactive 
protein, PCT and D-dimer with a further decrease in the hemo-
globin concentration. International normalized ratio and platelets 
count were within normal limits. At a second evaluation, transtho-
racic echocardiography revealed hypokinesia of the inferior left 
ventricular wall and the inferior interventricular septum, with a 
mild decrease in the left ventricular ejection fraction (57–58% in 
FIGURE 1. Disease course of 
the infected infant: timeta-
ble of laboratory tests (A) and 
clinical events (B). CRP indi-
cates C-reactive protein; INR, 
international normalized ratio; 
NT-pro-BNP, N-terminal pro-
brain natriuretic peptide; TnT, 
troponin T.
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parasternal short-axis view, 52.7% in biplane Simpson’s method). 
No inotropic support was required at the time. However, packed red 
blood cells were transfused, and empiric treatment with intravenous 
immunoglobulins (IVIGs) was started (2 g/kg in 24 hours). Between 
days 3 and 6, a decrease of cardiac and inflammatory markers was 
evident. On day 4, transthoracic echocardiography showed ejection 
fraction recovery with normal left ventricular dimensions, while 
mild dyskinesia of the inferior left ventricular wall and the inferior 
interventricular septum persisted. No specific signs of abnormal 
repolarization emerged from the electrocardiographic traces. On day 
5, heart rate was recorded stable and in the normal range (140–150 
bpm). The last determination of N-terminal pro-brain natriuretic 
peptide was 279 ng/L and D-dimer 1692 µg/L. Pre- and posttreat-
ment laboratory values and clinical events are presented in Figure 1.
To further investigate gastrointestinal symptoms, a test for 
the detection of adenovirus and rotavirus antigens on a stool sample 
was performed resulting negative. Search for other possible cardio-
tropic viral agents (including coxsackievirus, Epstein-Barr virus, 
mumps virus, parvovirus B19, adenovirus, varicella zoster virus, 
measles morbillivirus) plus Legionella pneumophila and Myco-
plasma pneumoniae IgM resulted negative. Antibiotic treatment 
was discontinued on day 5, after blood cultures proved negative.
DISCUSSION
Exuberant host immune response has been proposed as a 
driving mechanism for tissue damage in adults with SARS-CoV-2 
infection, regardless of the viral load. Cytokines levels, IL-6 in par-
ticular, seem to play a crucial role and may be considered as bio-
markers for risk stratification and prognosis. On this background, 
treatment strategies have been focusing on immune-modulation 
using monoclonal anti-IL-6 receptor antibody (Tocilizumab) or 
corticosteroids.1
In children, milder course of the COVID-19 disease has 
been explained with the so-called trained immunity, an enhanced 
state of activation of the immune system, induced by frequent viral 
infection and vaccines, and resulting in a more effective defense 
against different pathogens. In infants, however, relatively low lev-
els of the trained immunity have been proposed to explain more 
severe clinical presentation.3
Besides pulmonary damage, the most recent literature 
related to COVID-19 has reported an increased risk of cardiac 
complications including heart failure, myocardial infarction and 
arrhythmias in SARS-CoV-2-positive adults.4 In pediatric patients 
with paucisymptomatic SARS-CoV-2 infection, no cases of major 
heart injury have been reported yet, while increased cardiac bio-
markers have been described in a 55-day-old female infant with 
severe pulmonary involvement caused by SARS-CoV-2.2
No single clear mechanism responsible for cardiovascular 
complications in COVID-19 has been identified yet, but several 
possible options have been postulated, including direct acute 
direct myocardial injury (acute viral myocarditis), thrombotic 
events (type 1 myocardial infarction), microangiopathy and tach-
ycardia (type 2 myocardial infarction). The enhanced systemic 
inflammation response seems to be tightly related to all these 
mechanisms.5
Of note, in our patient, IL-6 peak reached values 33 times 
the upper limit of normal, preceding the rise of polymerase chain 
reaction, PCT, D-dimer and the reduction of hemoglobin concentra-
tion. IL-6 elevation was otherwise concurrent with cardiac marker 
elevation, preceding echocardiographic signs. Remarkably, NT-
pro-BNP reached values as high as those reported in children suf-
fering from acute heart failure or fulminant myocarditis.6
Among treatment options, we discarded corticosteroids 
because of the lack of univocal guidelines proving their effectiveness 
and because of concern related to their short- and long-term adverse 
effects in the context of SARS-CoV-2-infected patients.
IVIGs are commonly used to treat inflammatory diseases 
involving the heart in virtue of their immune-modulating activ-
ity, and their potential benefit in myocarditis treatment has been 
postulated. The choice to treat our patient using IVIG took into 
consideration their downregulatory effect on antibody and cytokine 
synthesis and inhibition of the leukocytes binding to the vascular 
endothelium. Indeed, our patient showed a good response to the 
treatment with IVIG.7
In our case, the suspicion of myocarditis was based on clini-
cal presentation, echocardiographic findings, typical localization 
and cardiac markers elevation.
Although the most specific diagnostic tools (cardiovascu-
lar magnetic resonance and endomyocardial biopsy) could not be 
employed due to the urgency and the young age of the patient, a 
clinical diagnosis was fulfilled anyway.8
Despite this, our report emphasizes the role of inflammation 
as a trigger for damage involving organs other than the lungs. Even 
in the absence of respiratory symptoms, the elevation of IL-6 is a 
possible early warning sign appearing to be of relevance also in 
youngest individuals with SARS-CoV-2 infection.
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HAND CELLULITIS AND ABSCESS FROM A 
KINKAJOU BITE
A Case Report and Review of Kinkajou Bites in Humans
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Abstract: Medical literature on the microbiology of kinkajou bites is 
scarce. We present a patient presenting with hand cellulitis and abscess 
after a kinkajou bite that grew Aggregatibacter actinomycetemcomitans and 
Fusobacterium nucleatum. We review the literature regarding microbiology 
and management of kinkajou bites.
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